Get the Latest Investment Ideas Delivered Straight to Your Inbox.

TICKERS: TCS

Coverage Initiated on Tech Firm Servicing Healthcare Industry
Research Report

Source:

Haywood Securities presented the thesis for investment in this company, including its growth drivers and continued focus on acquisition.

In a Dec. 6 research note, analyst Pardeep Sangha reported Haywood Securities initiated coverage on TECSYS Inc. (TCS:TSE) with a Buy rating and a CA$19 per share 12-month target price. The stock is currently trading at around CA$13.55 per share. The company provides supply chain management software and solutions to the healthcare and complex distribution sectors.

"TECSYS is a profitable, growth-oriented technology company that also has a consistent record of increasing its dividend," Sangha indicated.

According to Sangha, the reasons Haywood likes the company as an investment include:

1. Return to growth. Sangha noted that Haywood forecasts revenue growth for TECSYS of 10% in FY19 and 18% in FY20, in part due to increased healthcare spending and effects of the Democratic wins in the recent mid-term elections. Other growth drivers will be the company's acquisition in November and its successful launch of a hospital pharmacy module in October.

Another indicator of future growth is a record backlog of signed but not delivered contracts at the end of Q2 FY19 (Oct. 31, 2018). At that time, the backlog value totaled CA$51.7 million, versus CA$42.4 million a year earlier. Also year over year, the company had increased bookings from existing clients by 196%.

2. Renewed concentration on acquisitions. In November, TECSYS acquired OrderDynamics for CA$13.4 million. Sangha described it as complementary to the company's core business, providing cross-selling opportunities and immediately boosting revenue in Q3 FY19 by about CA$7 million.

3. Strong balance sheet. At the end of the same quarter, TECSYS had CA$21.7 million in cash and no debt, positioning it well for future acquisitions and a possible dividend increase.

4. Large market opportunity. TECSYS has an estimated CA$9.6 billion opportunity in the healthcare market alone. However, to date it has captured only an estimated 6% share of the 500 healthcare systems in the U.S. and penetrated its own accounts by 12%.

5. Solid track record. For the past six years, market researcher Gartner has categorized TECSYS as "visionary" in warehouse management. The tech company is led by an "experienced management team," with Peter Brereton having been its CEO since 1998. Peter's brother, Dave Brereton, founded the company and is the board's executive chairman. In addition, "management's interests are aligned with shareholders," noted Sangha.

6. Current good entry point. Sangha highlighted that TECSYS' current share price "presents a buying opportunity for investors," because it has dropped from its high of CA$17.50 in August due to general market sell-off, and the company's future prospects look good.

[NLINSERT]

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from Haywood Securities, TECSYS Inc., December 6, 2018

Haywood Securities, or certain of its affiliated companies, may from time to time receive a portion of commissions or other fees derived from the trading or financings conducted by other affiliated companies in the covered security. Haywood analysts are salaried employees who may receive a performance bonus that may be derived, in part, from corporate finance income.

Haywood Securities, Inc., and Haywood Securities (USA) Inc. do have officers in common however, none of those common officers affect or control the ratings given a specific issuer or which issuer will be the subject of Research coverage. In addition, the firm does maintain and enforce written policies and procedures reasonably designed to prevent influence on the activities of affiliated analysts.

Analyst Certification: I, Pardeep S. Sangha, hereby certify that the views expressed in this report (which includes the rating assigned to the issuer’s shares as well as the analytical substance and tone of the report) accurately reflect my/our personal views about the subject securities and the issuer. No part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations.

Important Disclosures

Other material conflict of interest of the research analyst of which the research analyst or Haywood Securities Inc. knows or has reason to know at the time of publication or at the time of public appearance: n/a.




Want to read more about Technology and Healthcare Services investment ideas?
Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe